Abstract

Pathogenic fungi have the capacity to form tenacious biofilm structures that are notoriously unresponsive to antifungal therapies. Fungal biofilms are ubiquitous, located all over the human host, including the oral cavity, respiratory tract, gastrointestinal tract, urinary tract, wounds and upon biomedical devices. This latter category represents one of the greatest hurdles in clinical management, where the presence of inert substrates such as a catheter provides a reservoir for fungal biofilm development. Here, Candida albicans is the most adept at forming biofilms and is the principal nosocomial fungal pathogen based on its high rates of mortality, which are often associated with the biofilm lifestyle. This review will summarise some of the key fungal biofilm-forming organisms and their clinical significance and will discuss current and novel strategies to manage these hard-to-treat infections based on in vitro and in vivo studies.

Original languageEnglish
Pages (from-to)114-20
Number of pages7
JournalInternational journal of antimicrobial agents
Volume43
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Biofilms
Candida albicans
Urinary Tract
Respiratory System
Mouth
Gastrointestinal Tract
Life Style
Fungi
Catheters
Equipment and Supplies
Mortality
Wounds and Injuries
Infection

Keywords

  • Antifungal Agents
  • Biofilms
  • Fungi
  • Humans

Cite this

@article{9e5127c03a6c407886fd90cebab669b5,
title = "Strength in numbers: antifungal strategies against fungal biofilms",
abstract = "Pathogenic fungi have the capacity to form tenacious biofilm structures that are notoriously unresponsive to antifungal therapies. Fungal biofilms are ubiquitous, located all over the human host, including the oral cavity, respiratory tract, gastrointestinal tract, urinary tract, wounds and upon biomedical devices. This latter category represents one of the greatest hurdles in clinical management, where the presence of inert substrates such as a catheter provides a reservoir for fungal biofilm development. Here, Candida albicans is the most adept at forming biofilms and is the principal nosocomial fungal pathogen based on its high rates of mortality, which are often associated with the biofilm lifestyle. This review will summarise some of the key fungal biofilm-forming organisms and their clinical significance and will discuss current and novel strategies to manage these hard-to-treat infections based on in vitro and in vivo studies.",
keywords = "Antifungal Agents, Biofilms, Fungi, Humans",
author = "Gordon Ramage and Robertson, {Shaun N} and Craig Williams",
note = "Copyright {\circledC} 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.",
year = "2014",
month = "2",
doi = "10.1016/j.ijantimicag.2013.10.023",
language = "English",
volume = "43",
pages = "114--20",
journal = "International journal of antimicrobial agents",
issn = "0924-8579",
publisher = "Elsevier B.V.",
number = "2",

}

Strength in numbers : antifungal strategies against fungal biofilms. / Ramage, Gordon; Robertson, Shaun N; Williams, Craig.

In: International journal of antimicrobial agents, Vol. 43, No. 2, 02.2014, p. 114-20.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Strength in numbers

T2 - antifungal strategies against fungal biofilms

AU - Ramage, Gordon

AU - Robertson, Shaun N

AU - Williams, Craig

N1 - Copyright © 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

PY - 2014/2

Y1 - 2014/2

N2 - Pathogenic fungi have the capacity to form tenacious biofilm structures that are notoriously unresponsive to antifungal therapies. Fungal biofilms are ubiquitous, located all over the human host, including the oral cavity, respiratory tract, gastrointestinal tract, urinary tract, wounds and upon biomedical devices. This latter category represents one of the greatest hurdles in clinical management, where the presence of inert substrates such as a catheter provides a reservoir for fungal biofilm development. Here, Candida albicans is the most adept at forming biofilms and is the principal nosocomial fungal pathogen based on its high rates of mortality, which are often associated with the biofilm lifestyle. This review will summarise some of the key fungal biofilm-forming organisms and their clinical significance and will discuss current and novel strategies to manage these hard-to-treat infections based on in vitro and in vivo studies.

AB - Pathogenic fungi have the capacity to form tenacious biofilm structures that are notoriously unresponsive to antifungal therapies. Fungal biofilms are ubiquitous, located all over the human host, including the oral cavity, respiratory tract, gastrointestinal tract, urinary tract, wounds and upon biomedical devices. This latter category represents one of the greatest hurdles in clinical management, where the presence of inert substrates such as a catheter provides a reservoir for fungal biofilm development. Here, Candida albicans is the most adept at forming biofilms and is the principal nosocomial fungal pathogen based on its high rates of mortality, which are often associated with the biofilm lifestyle. This review will summarise some of the key fungal biofilm-forming organisms and their clinical significance and will discuss current and novel strategies to manage these hard-to-treat infections based on in vitro and in vivo studies.

KW - Antifungal Agents

KW - Biofilms

KW - Fungi

KW - Humans

U2 - 10.1016/j.ijantimicag.2013.10.023

DO - 10.1016/j.ijantimicag.2013.10.023

M3 - Article

VL - 43

SP - 114

EP - 120

JO - International journal of antimicrobial agents

JF - International journal of antimicrobial agents

SN - 0924-8579

IS - 2

ER -